116 related articles for article (PubMed ID: 15531454)
21. The prognostic value of TRAIL and its death receptors in cervical cancer.
Maduro JH; Noordhuis MG; ten Hoor KA; Pras E; Arts HJ; Eijsink JJ; Hollema H; Mom CH; de Jong S; de Vries EG; de Bock GH; van der Zee AG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):203-11. PubMed ID: 19695437
[TBL] [Abstract][Full Text] [Related]
22. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
24. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
25. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma.
Martini M; D'Alò F; Pierconti F; Ricci R; Capelli A; Leone G; Larocca LM
Haematologica; 2000 Oct; 85(10):1019-23. PubMed ID: 11025591
[TBL] [Abstract][Full Text] [Related]
26. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
Wolf S; Mertens D; Pscherer A; Schroeter P; Winkler D; Gröne HJ; Hofele C; Hemminki K; Kumar R; Steineck G; Döhner H; Stilgenbauer S; Lichter P
Int J Cancer; 2006 Apr; 118(7):1831-5. PubMed ID: 16217763
[TBL] [Abstract][Full Text] [Related]
27. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
Horak P; Pils D; Kaider A; Pinter A; Elandt K; Sax C; Zielinski CC; Horvat R; Zeillinger R; Reinthaller A; Krainer M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8585-91. PubMed ID: 16361541
[TBL] [Abstract][Full Text] [Related]
28. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
[TBL] [Abstract][Full Text] [Related]
29. Death receptor 4 variants and colorectal cancer risk.
Frank B; Shanmugam KS; Beckmann L; Hemminki K; Brenner H; Hoffmeister M; Chang-Claude J; Burwinkel B
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):2002-5. PubMed ID: 17035413
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
31. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
[TBL] [Abstract][Full Text] [Related]
32. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer.
Horak P; Pils D; Roessler M; Tomek S; Elandt K; Zeillinger R; Zielinski C; Krainer M
Gynecol Oncol; 2005 May; 97(2):514-8. PubMed ID: 15863153
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma.
Camacho E; Beà S; Salaverría I; López-Guillermo A; Puig X; Benavente Y; de Sanjosé S; Campo E; Hernández L
Int J Cancer; 2006 Jan; 118(2):357-63. PubMed ID: 16080195
[TBL] [Abstract][Full Text] [Related]
34. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
35. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.
Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP
Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626
[TBL] [Abstract][Full Text] [Related]
36. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Wagner KW; Punnoose EA; Januario T; Lawrence DA; Pitti RM; Lancaster K; Lee D; von Goetz M; Yee SF; Totpal K; Huw L; Katta V; Cavet G; Hymowitz SG; Amler L; Ashkenazi A
Nat Med; 2007 Sep; 13(9):1070-7. PubMed ID: 17767167
[TBL] [Abstract][Full Text] [Related]
37. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
39. A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma.
Hellmig S; Fischbach W; Goebeler-Kolve ME; Fölsch UR; Hampe J; Schreiber S
Am J Gastroenterol; 2005 Dec; 100(12):2644-9. PubMed ID: 16393214
[TBL] [Abstract][Full Text] [Related]
40. IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression.
Tanaka F; Kawakami A; Tamai M; Nakamura H; Iwanaga N; Izumi Y; Arima K; Aratake K; Huang M; Kamachi M; Ida H; Origuchi T; Eguchi K
Int J Mol Med; 2005 May; 15(5):833-9. PubMed ID: 15806306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
